72 related articles for article (PubMed ID: 28875726)
1. Elevated expression of a pharmacologic Polycomb signature predicts poor prognosis in gastric and breast cancer.
Clermont PL; Fornaro L; Crea F
Epigenomics; 2017 Oct; 9(10):1329-1335. PubMed ID: 28875726
[TBL] [Abstract][Full Text] [Related]
2. TP53 genomic status regulates sensitivity of gastric cancer cells to the histone methylation inhibitor 3-deazaneplanocin A (DZNep).
Cheng LL; Itahana Y; Lei ZD; Chia NY; Wu Y; Yu Y; Zhang SL; Thike AA; Pandey A; Rozen S; Voorhoeve PM; Yu Q; Tan PH; Bay BH; Itahana K; Tan P
Clin Cancer Res; 2012 Aug; 18(15):4201-12. PubMed ID: 22675170
[TBL] [Abstract][Full Text] [Related]
3. Polycomb genes and cancer: time for clinical application?
Crea F; Paolicchi E; Marquez VE; Danesi R
Crit Rev Oncol Hematol; 2012 Aug; 83(2):184-93. PubMed ID: 22112692
[TBL] [Abstract][Full Text] [Related]
4. Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells.
Tan J; Yang X; Zhuang L; Jiang X; Chen W; Lee PL; Karuturi RK; Tan PB; Liu ET; Yu Q
Genes Dev; 2007 May; 21(9):1050-63. PubMed ID: 17437993
[TBL] [Abstract][Full Text] [Related]
5. 3-Deazaneplanocin A suppresses aggressive phenotype-related gene expression in an oral squamous cell carcinoma cell line.
Hatta M; Naganuma K; Kato K; Yamazaki J
Biochem Biophys Res Commun; 2015 Dec 4-11; 468(1-2):269-73. PubMed ID: 26505792
[TBL] [Abstract][Full Text] [Related]
6. S-adenosylhomocysteine hydrolase inhibition by 3-deazaneplanocin A analogues induces anti-cancer effects in breast cancer cell lines and synergy with both histone deacetylase and HER2 inhibition.
Hayden A; Johnson PW; Packham G; Crabb SJ
Breast Cancer Res Treat; 2011 May; 127(1):109-19. PubMed ID: 20556507
[TBL] [Abstract][Full Text] [Related]
7. 3-Deazaneplanocin A May Directly Target Putative Cancer Stem Cells in Biliary Tract Cancer.
Mayr C; Wagner A; Stoecklinger A; Jakab M; Illig R; Berr F; Pichler M; Di Fazio P; Ocker M; Neureiter D; Kiesslich T
Anticancer Res; 2015 Sep; 35(9):4697-705. PubMed ID: 26254359
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic Modifications with DZNep, NaBu and SAHA in Luminal and Mesenchymal-like Breast Cancer Subtype Cells.
Dagdemir A; Judes G; Lebert A; Echegut M; Karsli-Ceppioglu S; Rifaï K; Daures M; Ngollo M; Dubois L; Penault-Llorca F; Bignon YJ; Bernard-Gallon D
Cancer Genomics Proteomics; 2016; 13(4):291-303. PubMed ID: 27365379
[TBL] [Abstract][Full Text] [Related]
9. STAT3 signaling drives EZH2 transcriptional activation and mediates poor prognosis in gastric cancer.
Pan YM; Wang CG; Zhu M; Xing R; Cui JT; Li WM; Yu DD; Wang SB; Zhu W; Ye YJ; Wu Y; Wang S; Lu YY
Mol Cancer; 2016 Dec; 15(1):79. PubMed ID: 27938379
[TBL] [Abstract][Full Text] [Related]
10. Identification of a TLR2-regulated gene signature associated with tumor cell growth in gastric cancer.
West AC; Tang K; Tye H; Yu L; Deng N; Najdovska M; Lin SJ; Balic JJ; Okochi-Takada E; McGuirk P; Keogh B; McCormack W; Bhathal PS; Reilly M; Oshima M; Ushijima T; Tan P; Jenkins BJ
Oncogene; 2017 Sep; 36(36):5134-5144. PubMed ID: 28481875
[TBL] [Abstract][Full Text] [Related]
11. Analysis of the antiproliferative effects of 3-deazaneoplanocin A in combination with standard anticancer agents in rhabdoid tumor cell lines.
Unland R; Borchardt C; Clemens D; Kool M; Dirksen U; Frühwald MC
Anticancer Drugs; 2015 Mar; 26(3):301-11. PubMed ID: 25415657
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical analysis of polycomb group protein expression in advanced gastric cancer.
Lee H; Yoon SO; Jeong WY; Kim HK; Kim A; Kim BH
Hum Pathol; 2012 Oct; 43(10):1704-10. PubMed ID: 22520951
[TBL] [Abstract][Full Text] [Related]
13. 3-Deazaneplanocin A is a promising therapeutic agent for ovarian cancer cells.
Shen L; Cui J; Pang YX; Ma YH; Liu PS
Asian Pac J Cancer Prev; 2013; 14(5):2915-8. PubMed ID: 23803053
[TBL] [Abstract][Full Text] [Related]
14. Relative Prognostic and Predictive Value of Gene Signature and Histologic Grade in Estrogen Receptor-Positive, HER2-Negative Breast Cancer.
Iwamoto T; Kelly C; Mizoo T; Nogami T; Motoki T; Shien T; Taira N; Hayashi N; Niikura N; Fujiwara T; Doihara H; Matsuoka J
Clin Breast Cancer; 2016 Apr; 16(2):95-100.e1. PubMed ID: 26631838
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic inactivation of paired box gene 5, a novel tumor suppressor gene, through direct upregulation of p53 is associated with prognosis in gastric cancer patients.
Li X; Cheung KF; Ma X; Tian L; Zhao J; Go MY; Shen B; Cheng AS; Ying J; Tao Q; Sung JJ; Kung HF; Yu J
Oncogene; 2012 Jul; 31(29):3419-30. PubMed ID: 22105368
[TBL] [Abstract][Full Text] [Related]
16. Elevated HMGA2 expression is associated with cancer aggressiveness and predicts poor outcome in breast cancer.
Wu J; Zhang S; Shan J; Hu Z; Liu X; Chen L; Ren X; Yao L; Sheng H; Li L; Ann D; Yen Y; Wang J; Wang X
Cancer Lett; 2016 Jul; 376(2):284-92. PubMed ID: 27063096
[TBL] [Abstract][Full Text] [Related]
17. Elevated nuclear S100P expression is associated with poor survival in early breast cancer patients.
Maciejczyk A; Łacko A; Ekiert M; Jagoda E; Wysocka T; Matkowski R; Hałoń A; Györffy B; Lage H; Surowiak P
Histol Histopathol; 2013 Apr; 28(4):513-24. PubMed ID: 23364898
[TBL] [Abstract][Full Text] [Related]
18. LGR5 Is a Gastric Cancer Stem Cell Marker Associated with Stemness and the EMT Signature Genes NANOG, NANOGP8, PRRX1, TWIST1, and BMI1.
Wang B; Chen Q; Cao Y; Ma X; Yin C; Jia Y; Zang A; Fan W
PLoS One; 2016; 11(12):e0168904. PubMed ID: 28033430
[TBL] [Abstract][Full Text] [Related]
19. microRNA-217 inhibits tumor progression and metastasis by downregulating EZH2 and predicts favorable prognosis in gastric cancer.
Chen DL; Zhang DS; Lu YX; Chen LZ; Zeng ZL; He MM; Wang FH; Li YH; Zhang HZ; Pelicano H; Zhang W; Xu RH
Oncotarget; 2015 May; 6(13):10868-79. PubMed ID: 25869101
[TBL] [Abstract][Full Text] [Related]
20. HOX transcript antisense intergenic RNA represses E-cadherin expression by binding to EZH2 in gastric cancer.
Chen WM; Chen WD; Jiang XM; Jia XF; Wang HM; Zhang QJ; Shu YQ; Zhao HB
World J Gastroenterol; 2017 Sep; 23(33):6100-6110. PubMed ID: 28970725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
